Researchers at UC San Francisco have identified blood biomarkers that detect early signs of Alzheimer's disease in cognitively normal midlife adults. The study measured tau and amyloid plaque levels in blood samples and found these biomarkers correlated with subtle cognitive differences and predicted a higher risk of cognitive decline. This breakthrough allows detection of Alzheimer's pathology years before symptoms appear, potentially enabling earlier interventions. The findings represent a major advance in identifying at-risk individuals who could benefit from preventive strategies before dementia develops.
